Chemed Q4 Revenue Flat at $639M, EPS Falls 6%, 2026 Guidance 6.5% Below Consensus
Chemed reported flat Q4 revenue of $639.3 million and adjusted EPS of $6.42, down 6% year-over-year and missing analyst forecasts. Operating margin declined to 15.7% from 17.8% and full-year 2026 earnings guidance midpoint is 6.5% below consensus, prompting a 15.6% stock selloff.
1. Q4 2025 Financial Results
Chemed posted fourth-quarter revenue of $639.3 million, essentially flat year-over-year, and adjusted EPS of $6.42, a 6% decline from the prior period, both figures falling short of analyst expectations.
2. Profitability Pressure
The company’s operating margin dropped to 15.7% from 17.8% in the same quarter last year as operating expenses grew faster than sales, highlighting emerging cost pressures.
3. 2026 Outlook
Management’s full-year 2026 earnings guidance midpoint sits approximately 6.5% below existing analyst consensus, reflecting conservative assumptions on revenue growth and margin expansion.
4. Stock Reaction
Shares plunged about 15.6% on the earnings miss and cautious outlook, representing one of the largest intraday moves for the typically low-volatility healthcare services stock.